PRESS RELEASE published on 10/24/2024 at 19:30, 1 year 1 month ago Inside Information / Other news releases ABIONYX Pharma's RACERS study on CER-001 shows positive impact on cognitive impairment in brain-fog patients, presenting new clinical results at ASN 2024 Annual Meeting. Potential treatment for neuroinflammation ABIONYX Pharma CER-001 Brain-fog Neuroinflammation RACERS Study
BRIEF published on 10/21/2024 at 20:05, 1 year 1 month ago ABIONYX Pharma reçoit un avis favorable de l'EMA pour le CER-001 ABIONYX Pharma CER-001 EMA Déficience LCAT AMM
BRIEF published on 10/21/2024 at 20:05, 1 year 1 month ago ABIONYX Pharma receives positive EMA opinion for CER-001 ABIONYX Pharma CER-001 EMA AMM LCAT Deficiency
PRESS RELEASE published on 10/21/2024 at 20:00, 1 year 1 month ago Informations privilégiées / Autres communiqués ABIONYX Pharma reçoit un avis positif de l'EMA pour le CER-001 dans la Déficience en LCAT. L'EMA admissible à la soumission de deux lots prospectifs de validation du procédé de fabrication ABIONYX Pharma CER-001 EMA LCAT Validation Du Procédé
PRESS RELEASE published on 10/21/2024 at 20:00, 1 year 1 month ago Inside Information / Other news releases ABIONYX Pharma receives positive feedback from EMA for CER-001 in LCAT Deficiency, allowing submission of data from 2 prospective process validation batches for MAA manufacturing ABIONYX Pharma CER-001 EMA LCAT Deficiency Process Validation Batches
BRIEF published on 08/22/2024 at 18:05, 1 year 3 months ago ABIONYX Pharma : Bilan du 1er semestre 2024 Chiffre D'affaires Biotechnologie Trésorerie Levée De Fonds ABIONYX Pharma
BRIEF published on 08/22/2024 at 18:05, 1 year 3 months ago ABIONYX Pharma: Review of the first half of 2024 Biotechnology Fundraising Treasury Turnover ABIONYX Pharma
PRESS RELEASE published on 08/22/2024 at 18:00, 1 year 3 months ago Informations privilégiées / Autres communiqués ABIONYX Pharma publie sa position de trésorerie du 1er semestre 2024 avec un chiffre d’affaires consolidé de 2,4 M€. Levée de fonds de 3,4 M€ pour renforcer la trésorerie Chiffre D'affaires Biotechnologie Trésorerie Levée De Fonds ABIONYX Pharma
PRESS RELEASE published on 08/22/2024 at 18:00, 1 year 3 months ago Inside Information / Other news releases ABIONYX Pharma reports €2.4m sales and €5.3m cash position for H1 2024, focused on innovative therapies. Raised €3.4m for sepsis program in the US Sales Cash Position Innovative Therapies ABIONYX Pharma Sepsis
BRIEF published on 07/01/2024 at 09:27, 1 year 5 months ago ABIONYX Successfully Completes €3.4 Million Capital Increase Capital Increase Biotech Shares And Warrants ABIONYX Sepsis Development
Published on 12/05/2025 at 21:45, 40 minutes ago When the Architecture Becomes Visible: The SMX Revaluation Explained
Published on 12/05/2025 at 21:30, 55 minutes ago The Identity Layer Beneath Everything: Why Markets Are Revaluing SMX All at Once
Published on 12/05/2025 at 21:20, 1 hour 5 minutes ago Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement
Published on 12/05/2025 at 21:00, 1 hour 25 minutes ago The Repricing Event: Why Multiple Global Industries Are Suddenly Moving Toward SMX
Published on 12/05/2025 at 20:25, 2 hours ago The Feedback Loop: Why SMX's Adoption in One Industry Accelerates Interest in All the Others
Published on 12/05/2025 at 22:15, 10 minutes ago CPI PROPERTY GROUP - Changes in Shareholding and Board of Directors
Published on 12/05/2025 at 22:12, 13 minutes ago EQS-Adhoc: CPI PROPERTY GROUP - Change to Distribution Policy
Published on 12/05/2025 at 18:58, 3 hours 27 minutes ago EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:15, 4 hours 10 minutes ago Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:18, 5 hours 7 minutes ago La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 5 hours 7 minutes ago The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 7 hours 14 minutes ago Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 7 hours 14 minutes ago Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 8 hours 27 minutes ago RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE
